Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
monosialotetrahexosylganglioside + recombinant human erythropoietin
- Development stage
- Unknown
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Intramuscular, Subcutaneous
01
Overview
This is a combination therapy consisting of monosialotetrahexosylganglioside (GM1) and recombinant human erythropoietin. GM1 is a glycosphingolipid with antioxidant and neuroprotective properties that has been studied for conditions like Parkinson's disease, stroke, and protection against drug-induced neurotoxicity. Recombinant human erythropoietin stimulates red blood cell production and is primarily used to treat anemia associated with chronic kidney disease, chemotherapy, or HIV treatment. The combination may potentially offer both neuroprotective effects and hematological benefits, though specific research on this combination is limited.
- Other names
- GM1 + recombinant human erythropoietinGM1 + epoetin
02
Targets
Erythropoietin ReceptorCholesterolSNCA (Alpha-synuclein)
Beyond the preview
Go deeper on monosialotetrahexosylganglioside + recombinant human erythropoietin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on monosialotetrahexosylganglioside + recombinant human erythropoietin.